https://www.cochrane.org/fr/CD014089/MUSKEL_quels-sont-les-benefices-et-les-risques-des-medicaments-qui-augmentent-le-flux-sanguin-vers-les 2023 United Kingdom review of literature french abstract Ratio secondary raynaud's phenomenon Increased Current Reformed Smoker, Years Unknown increased vascular flow risks and benefits Fear Score 5 Medication Placebo raynaud disease What Month is it Loss of Chromosome 5 Intensity and Distress 5 drug, nos Flow Extremities Clinical Status Ordinal Scale Outcome 5 extremities Version research report ECOG Performance Status 5 anthelmintics Severity of Symptom Score 5 No Flow Thought Score 5 raynaud phenomenon Death Related to Adverse Event Agreement Score 5 Illness Intrusiveness Rating 5 Raynaud Phenomenon Gleason Grade Group 5 risk assessment placebos Phase V Trial Regulatory Report Phosphodiesterase Inhibitor Neck Pain Score 5 phosphodiesterase 5 inhibitors Upset Score 5 albumin/globulin ratio Increase Flux GDC Therapeutic Agent Terminology